Premium
Expanding screening for rare metabolic disease in the newborn: An analysis of costs, effect and ethical consequences for decision‐making in Finland
Author(s) -
AuttiRämö Ilona,
Måkelå Marjukka,
Sintonen Harri,
Koskinen Hanna,
Laajalahti Liisa,
Halila Ritva,
Kååriåinen Helena,
Lapatto Risto,
Nåntösalonen Kirsti,
Pulkki Kari,
Renlund Martin,
Salo Matti,
Tyni Tiina
Publication year - 2005
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2005.tb02056.x
Subject(s) - newborn screening , medicine , congenital hypothyroidism , pediatrics , congenital adrenal hyperplasia , metabolic disease , endocrinology , thyroid
Aim: Currently, the only metabolic disorder that newborns are screened for in Finland is congenital hypothyroidism. A proposal to start a pilot study on screening for other rare metabolic diseases using tandem mass spectrometry prompted a health technology assessment project on the effect and costs of expanded newborn screening programme options. Method: A modelling study using data from current published studies, healthcare registers and expert opinion. Results: The annual running cost of screening 56 000 newborns for the chosen five disorders (congenital adrenal hyperplasia, medium‐chain acyl‐CoA dehydrogenase deficiency [MCADD], long chain 3‐hydroxyacyl‐CoA dehydrogenase deficiency [LCHADD], phenylketonuria [PKU] and glutaric aciduria type 1 [GA 1]) was estimated to be €2.5 million or €45 per newborn when starting costs were included. The costs per quality‐adjusted life year (QALY) gained are a maximum of €25 500. Prevention of severe handicap in one newborn would reduce the costs to a maximum of €18 000 per QALY gained. Conclusions: Expanding the Finnish neonatal screening programme would require a new organization. The cost‐effectiveness, resources, ethics and equity need to be considered when deciding in favour of or against starting a new screening programme.